Andrew Fein has given his Buy rating due to a combination of factors that highlight Vertex Pharmaceuticals’ potential success ... which targets sodium channels in the peripheral nervous system, is ...

In the latest market close, Vertex Pharmaceuticals ... using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system ...

Vertex Pharmaceuticals Inc. ( (VRTX) ) has released its Q3 earnings. Here is a breakdown of the information Vertex Pharmaceuticals Inc.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vertex Pharmaceuticals (VRTX ... an exclusive model that considers these estimated changes and delivers an operational rating system. The Zacks Rank system, spanning from #1 (Strong Buy) to ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 5 years by 6.32% on an annualized basis producing an average annual return of 20.45%. Currently, Vertex Pharmaceuticals has a ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 1.26% to $470.36 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.16% ...

Vertex Pharmaceuticals (VRTX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, VRTX broke through the 20-day moving average ...

If you want to stay updated on the latest options trades for Vertex Pharmaceuticals, Benzinga Pro gives you real-time options trades alerts.